Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Rhea-AI Summary

Immatics (NASDAQ: IMTX) has announced upcoming presentations of its IMA203 TCR T-cell therapy at the 2025 ASCO Annual Meeting in Chicago. The presentations will feature:

1. An oral presentation with updated data from the Phase 1b trial of IMA203 in metastatic melanoma patients, including extended follow-up data since October 2024 and additional uveal melanoma patient data.

2. A trial-in-progress poster presentation on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior checkpoint inhibitor treatment.

The full abstracts will be available on the ASCO website on May 22, 2025, at 5:00 pm ET. The presentations are scheduled for May 31 and June 2, 2025, during the Developmental Therapeutics - Immunotherapy sessions.

Positive

• Advancement to Phase 3 clinical trial (SUPRAME) demonstrates progression in drug development pipeline
• Expanded patient data collection in Phase 1b trial shows continued clinical development momentum

Negative

• None.

Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois.

Updated data from the Phase 1b trial of IMA203 in patients with metastatic melanoma with substantially longer follow-up compared to the last presentation in October 2024, and including data from additional uveal melanoma patients enrolled since then, will be highlighted in an oral presentation.

In addition, a trial-in-progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a checkpoint inhibitor, will be presented at the conference.

Full abstracts will be available on the ASCO website on May 22, 2025, at 5:00 pm ET.

Oral Presentation 

Title: Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma
Presenting author: Martin Wermke, MD
Session: Developmental Therapeutics – Immunotherapy
Date / Time: May 31, 2025 / 3:00 – 6:00 pm CDT
Abstract ID: 2508

Poster Presentation 

Title: SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR T) vs investigator’s choice in patients with previously treated advanced cutaneous melanoma
Presenting author: Jason Luke, MD, FACP, FASCO
Session: Developmental Therapeutics - Immunotherapy
Date / Time: June 2, 2025 / 1:30 - 4:30 pm CDT
Abstract ID: TPS2673

About IMA203 TCR T-cell Therapy and Target PRAME
IMA203 is an autologous, engineered T-cell receptor T-cell therapy (TCR T) that targets PRAME, an intracellular protein displayed as a peptide antigen on the surface of multiple solid tumors via HLA-A*02:01, with minimal expression on healthy tissues. With precise targeting and a turnaround time of approximately 14 days, IMA203 has demonstrated a favorable clinical profile in patients with unmet medical needs.

IMA203 TCR T-cell therapy is currently being evaluated in a registration-enabling randomized controlled Phase 3 trial, “SUPRAME,” in patients with unresectable or metastatic cutaneous melanoma who have disease progression on or after at least one PD-1 inhibitor. In parallel, the Phase 1b clinical trial in patients with solid tumors expressing PRAME is ongoing with a focus on uveal melanoma.

About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T-cell receptors with the goal of enabling a robust and specific T-cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on Instagram and LinkedIn.

For more information, please contact:

Media
Trophic Communications
Phone: +49 151 74416179
immatics@trophic.eu

Immatics N.V.
Jordan Silverstein
Head of Strategy
Phone: +1 346 319-3325
InvestorRelations@immatics.com 

Attachment

• PDF Version

FAQ

What will Immatics present about IMA203 at ASCO 2025?

Immatics will present updated Phase 1b trial data for IMA203 in metastatic melanoma patients and a trial-in-progress poster on the SUPRAME Phase 3 study.

When will the IMTX ASCO 2025 presentation abstracts be available?

The full abstracts will be available on the ASCO website on May 22, 2025, at 5:00 pm ET.

What is the target population for Immatics' SUPRAME Phase 3 trial?

The SUPRAME trial targets patients with unresectable or metastatic cutaneous melanoma who have received prior checkpoint inhibitor treatment.

What types of melanoma patients are included in IMTX's IMA203 Phase 1b trial data?

The Phase 1b trial includes patients with metastatic melanoma and uveal melanoma.